Why the study?
Does troponin elevation predict adverse outcomes in patients with chronic cardiovascular disease?
Does troponin elevation predict adverse outcomes in patients with chronic cardiovascular disease?
Troponin elevations in chronic cardiovascular diseases, including valvular disease and heart failure, serve as important prognostic indicators for adverse outcomes.
Answers are grounded in this paper and cite their sources.
May enhance risk stratification in chronic cardiovascular disease; leaves open whether troponin-guided interventions improve outcomes.
Serum troponin elevation above the 99th percentile of the upper reference limit in healthy subjects (<0.01 ng/ml measured using currently available high-sensitivity cardiac troponin laboratory assays) is required to establish the diagnosis the diagnosis of myocardial necrosis in acute cardiovascular syndromes, as well as guide prognosis and therapy. In the perioperative period, for patients with cardiac disease undergoing noncardiac surgery, it is a particularly critical biomarker universally used to assess the myocardial damage. The value of troponin testing and elevation (as well as its significance) in patients with chronic cardiac valvular, vascular, and renal disease is relatively less well understood. This evidence-based review seeks to examine the currently available data assessing the significance of troponin elevation in certain chronic valvular and other disease states.
No takes yet. Share an insight, caveat, or question.
Harish Ramakrishna (2016) conducted a review in Chronic cardiovascular disease. Troponin elevation was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: